首页> 外文期刊>Journal of drug targeting >Biotin-streptavidin cross-bridging: A novel and feasible approach for targeting transplanted cells to damaged tissue
【24h】

Biotin-streptavidin cross-bridging: A novel and feasible approach for targeting transplanted cells to damaged tissue

机译:生物素-链霉亲和素交叉桥接:一种新颖可行的方法,可将移植细胞靶向受损组织

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Accumulating evidence indicates the positive impact of endothelium-derived cell therapy in vascular repair. However, low cell transplantation efficiency inevitably and greatly reduces the treatment efficacy of cell transplants. Purpose: To modify the surfaces of cells with polypeptides or small-molecule proteins that specifically recognize and bind to damaged tissue. Methods: We used a biotin-streptavidin binding approach to attach annexin V, which recognizes apoptotic cells, onto bEnd.3 cells that express vascular endothelial growth factor receptor 2 (VEGFR2) and verified that the modified cells could efficiently bind to dead cells in vitro. Results: We analyzed biotinylated VEGFR2-bEnd.3 cells, streptavidin-biotinylated VEGFR2-bEnd.3 cells, and biotinylated annexin V-streptavidin-biotinylated VEGFR2-bEnd.3 cells. Our results from flow cytometry analysis and immunofluorescent examination demonstrated that we successfully labeled the cells in a three-step process. Furthermore, we determined that the positive binding rate correlated with reagent concentration. Immunofluorescent examination illustrated that adding the biotinylated annexin V-streptavidin-biotinylated VEGFR2-bEnd.3 cells to dead cells led to the clustering and aggregation of the modified cells and the dead cells. Conclusions: Annexin V can be attached to bEnd.3 cells using a biotin-streptavidin binding approach, and the modified cells can specifically recognize and bind to dead cells.
机译:背景:越来越多的证据表明,内皮细胞治疗在血管修复中具有积极作用。然而,细胞移植效率低不可避免地会大大降低细胞移植的治疗效果。目的:用特异性识别并结合受损组织的多肽或小分子蛋白质修饰细胞表面。方法:我们使用生物素-链霉亲和素结合方法将识别凋亡细胞的膜联蛋白V连接到表达血管内皮生长因子受体2(VEGFR2)的bEnd.3细胞上,并验证了修饰后的细胞可以在体外与死细胞有效结合。结果:我们分析了生物素化的VEGFR2-bEnd.3细胞,链霉亲和素-生物素化的VEGFR2-bEnd.3细胞和生物素化的膜联蛋白V-链霉亲和素-生物素化的VEGFR2-bEnd.3细胞。我们从流式细胞仪分析和免疫荧光检查获得的结果表明,我们通过三步过程成功标记了细胞。此外,我们确定阳性结合率与试剂浓度相关。免疫荧光检查表明,向死细胞中添加生物素化的膜联蛋白V-链霉亲和素-生物素化的VEGFR2-bEnd.3细胞会导致修饰细胞和死细胞的聚集和聚集。结论:膜联蛋白V可以通过生物素-链霉亲和素结合方法与bEnd.3细胞结合,修饰后的细胞可以特异性识别并结合死细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号